Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02172482

Enrollment

63127

Registered

2014-06-24

Start date

2002-06-30

Completion date

Unknown

Last updated

2014-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice

Interventions

DRUGTiotropium bromide

Tiotropium bromide18 micrograms (capsule with powder for inhalation)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Men and women aged at least 40 years presenting with the symptoms of COPD

Exclusion criteria

* Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Design outcomes

Primary

Measure	Time frame
Change from baseline in breathlessness when walking/climbing stairs	Baseline, after 4 weeks
Change from baseline in overall severity of the clinical picture	Baseline, after 4 weeks of treatment
Occurrence of Adverse Events	up to 4 weeks
Change from baseline in breathlessness on Physical exercise	Baseline, after 4 weeks
Change from baseline in breathlessness during housework	Baseline, after 4 weeks
Change from baseline in breathlessness during everyday activities	Baseline, after 4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026